The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.
The development of vaccines that target tumor antigens in cancer has proven difficult. A major reason for this is that T cells specific for tumor self-antigens and neoantigens are eliminated or inactivated through mechanisms of tolerance. Antigen fusion strategies which increase the ability of vaccines to stimulate T cells that have escaped tolerance mechanisms, may have a particular potential as immunotherapies. This review highlights antigen fusion strategies that have been successful in stimulating the induction of T-cell immunity against cancer and counteracting tumor-associated tolerance. In preclinical studies, these strategies have shown to improve the potency of vectored vaccines through fusion of tumor antigen to proteins or protein domains that increase CD4+ T-cell help, CD8+ T-cell responses or both the CD4+ and CD8+ T-cell responses. However, in clinical trials such strategies seem to be less efficient when provided as a DNA vaccine. The first clinical trial using a viral vectored fusion-gene vaccine is expected to be tested as a partner in a heterologous prime-boost regimen directed against cervical cancer.
ISIM - Center for Medical Parasitology, Copenhagen, Denmark.
Emeline
E
Ragonnaud
ISIM - Center for Medical Parasitology, Copenhagen, Denmark.
Peter
P
Holst
Antigen engineering; DNA vaccine; breaking of tolerance; cancer; immunogenicity; low avidity T cells; viral vector vaccine